{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:40Z","timestamp":1785117580326,"version":"3.55.0"},"reference-count":30,"publisher":"IMR Press","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). Structural and electrical atrial remodeling are among the myocardial alterations associated with diabetes. Total atrial conduction time (TACT), derived from echocardiography, serves as a marker of atrial remodeling. However, the effect of SGLT2i on TACT remains unclear. Methods: In this prospective, single-center pilot study, 130 patients with T2DM and preserved left ventricular ejection fraction were enrolled between March and December 2022. After excluding patients who discontinued therapy or met other exclusion criteria, 107 patients (57 treated with dapagliflozin and 50 with empagliflozin) were included in the analysis. Echocardiographic and laboratory evaluations were performed at baseline and six months after initiation of SGLT2i therapy. TACT was defined as the mean time between the onset of the P wave in lead II and the peak A\u2032 wave on tissue Doppler imaging (PA-TDI). Paired statistical tests, correlation analyses, and multiple linear regression were used to identify independent predictors of \u0394 TACT. Results: After six months of SGLT2i therapy, significant reductions were observed in blood pressure, lipid levels, glycated hemoglobin (HbA1c), and body mass index values (all p &lt; 0.05). Moreover, echocardiography demonstrated significant decreases in the E\/e\u2032 ratios and mean PA-TDI duration (p &lt; 0.001). The \u0394 lateral E\/e\u2032 ratio and \u0394 body mass index (BMI) values were independently associated with \u0394 TACT (p = 0.001 and p = 0.026, respectively). The mean duration of SGLT2i use was 183 days. Conclusions: SGLT2i therapy was associated with a significant reduction in TACT among T2DM patients, suggesting potential improvements in atrial remodeling and diastolic function. These findings support the hypothesis that the cardiovascular benefits of SGLT2i may extend to atrial conduction properties. Nonetheless, larger randomized studies are warranted to confirm these observations.<\/jats:p>","DOI":"10.31083\/rcm50764","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:28:22Z","timestamp":1785115702000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors Shorten Echocardiography-Derived Total Atrial Conduction Time in Patients With Type 2 Diabetes Mellitus: A Prospective Pilot Study"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-6993","authenticated-orcid":true,"given":"Ercan","family":"Ta\u015ftan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Diyarbak\u0131r Selahaddin Eyyubi State Hospital, 21100 Diyarbak\u0131r, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-5672","authenticated-orcid":true,"given":"Fethullah","family":"Kayan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, SBU Diyarbak\u0131r Gazi Ya\u015fargil Training and Research Hospital, 21070 Diyarbak\u0131r, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-3586","authenticated-orcid":true,"given":"Song\u00fcl","family":"Beskisiz","sequence":"additional","affiliation":[{"name":"Department of \u0130nternal Medicine, Diyarbak\u0131r Gazi Ya\u015fargil Training and Research Hospital, 21070 Diyarbak\u0131r, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020; 41: 255\u2013323.","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine. 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. 2019; 380: 2295\u20132306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lamberts RR, Lingam SJ, Wang HY, Bollen IAE, Hughes G, Galvin IF, et al. Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovascular Diabetology. 2014; 13: 72.","DOI":"10.1186\/1475-2840-13-72"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013; 502: 372\u2013376.","DOI":"10.1038\/nature12537"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Yurista SR, Sillj\u00e9 HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovascular Diabetology. 2020; 19: 5.","DOI":"10.1186\/s12933-019-0984-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Nishinarita R, Niwano S, Niwano H, Nakamura H, Saito D, Sato T, et al. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. Journal of the American Heart Association. 2021; 10: e017483.","DOI":"10.1161\/JAHA.119.017483"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovascular Diabetology. 2019; 18: 165.","DOI":"10.1186\/s12933-019-0964-4"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"M\u00fcller P, Weijs B, Bemelmans NMAA, M\u00fcgge A, Eckardt L, Crijns HJGM, et al. Echocardiography-derived total atrial conduction time (PA-TDI duration): risk stratification and guidance in atrial fibrillation management. Clinical Research in Cardiology. 2021; 110: 1734\u20131742.","DOI":"10.1007\/s00392-021-01917-9"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Chao TF, Wang KL, Chuang CF, Chen SA, Yu WC. Atrium electromechanical interval in left ventricular diastolic dysfunction. European Journal of Clinical Investigation. 2012; 42: 117\u2013122.","DOI":"10.1111\/j.1365-2362.2011.02564.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Jain A, Avendano G, Dharamsey S, Dasmahapatra A, Agarwal R, Reddi A, et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation. 1996; 93: 1396\u20131402.","DOI":"10.1161\/01.cir.93.7.1396"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study [published erratum in Journal of the American College of Cardiology. 2010;56: 1612]. Journal of the American College of Cardiology. 2010; 55: 300\u2013305.","DOI":"10.1016\/j.jacc.2009.12.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovascular Diabetology. 2018; 17: 73.","DOI":"10.1186\/s12933-018-0717-9"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Wee CF, Teo YH, Teo YN, Syn NL, See RM, Leong S, et al. Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Imaging. 2022; 30: 153\u2013168.","DOI":"10.4250\/jcvi.2021.0159"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"De Vos CB, Weijs B, Crijns HJGM, Cheriex EC, Palmans A, Habets J, et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart. 2009; 95: 835\u2013840.","DOI":"10.1136\/hrt.2008.148528"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Merckx KL, De Vos CB, Palmans A, Habets J, Cheriex EC, Crijns HJGM, et al. Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial electrical activation. Journal of the American Society of Echocardiography. 2005; 18: 940\u2013944.","DOI":"10.1016\/j.echo.2005.03.022"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham study. JAMA. 1979; 241: 2035\u20132038.","DOI":"10.1001\/jama.241.19.2035"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care. 2009; 32: 1851\u20131856.","DOI":"10.2337\/dc09-0939"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology & Medicine. 2017; 104: 298\u2013310.","DOI":"10.1016\/j.freeradbiomed.2017.01.035"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascular Diabetology. 2019; 18: 15.","DOI":"10.1186\/s12933-019-0816-2"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Soliman Y, Abuelazm M, Amer BE, Hukamdad M, Ellabban MH, Hendi NI, et al. Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis. American Journal of Cardiovascular Drugs. 2024; 24: 629\u2013640.","DOI":"10.1007\/s40256-024-00661-5"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2021; 10: e022222.","DOI":"10.1161\/JAHA.121.022222"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovascular Diabetology. 2020; 19: 188.","DOI":"10.1186\/s12933-020-01162-w"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Wang TJ, Parise H, Levy D, D\u2019Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004; 292: 2471\u20132477.","DOI":"10.1001\/jama.292.20.2471"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Weijs B, de Vos CB, Tieleman RG, Pisters R, Cheriex EC, Prins MH, et al. Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace. 2011; 13: 1681\u20131687.","DOI":"10.1093\/europace\/eur261"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Tsang TSM, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. Journal of the American College of Cardiology. 2002; 40: 1636\u20131644.","DOI":"10.1016\/s0735-1097(02)02373-2"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Dziano JK, Ariyaratnam JP, Middeldorp ME, Sanders P, Elliott AD. Obesity and Atrial Fibrillation: From Mechanisms to Treatment. Heart, Lung & Circulation. 2025; 34: 1021\u20131032.","DOI":"10.1016\/j.hlc.2025.08.003"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Lam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, et al. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. European Heart Journal. 2013; 34: 676\u2013683.","DOI":"10.1093\/eurheartj\/ehs299"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/5\/10.31083\/RCM50764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:28:40Z","timestamp":1785115720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/5\/10.31083\/RCM50764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)02926-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm50764","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"50764"}}